Cite

    Stanley Cohan et al.. “The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide.” Multiple sclerosis journal, experimental, translational and clinical, vol. 7, no. 4, 2021, p. . http://access.bl.uk/ark:/81055/vdc_100141036918.0x00003c